Prevalence and Determinants of Subclinical Atherosclerosis in People Living with HIV on Antiretroviral Treatment in Hospitals in Kinshasa
DOI:
https://doi.org/10.17140/HARTOJ-9-139Keywords:
Subclinical atherosclerosis, HIV/AIDS, Antiretroviral therapy, Kinshasa/DRCAbstract
Introduction: The objective of this work was to identify the traditional, emerging, and therapeutic cardiometabolic risk factors for subclinical atherosclerosis in human immunodeficiency virus (HIV)-infected patients under antiretroviral treatment in the era of dolutegravir (DGT) in hospitals in the Kinshasa, Democratic Republic of the Congo (DRC).
Methods: This was a descriptive and analytical cross-sectional study held between January 2017 and December 2021 among people living with HIV (PLWHIV) on antiretroviral treatment (ART) for at least 6-months, supported in the structures of the Network Catholic of the Diocesan Office of Medical Works (BDOM) and at the University Clinics of Kinshasa (UCK). Sub clinical atherosclerosis was defined by: pulse pressure (PP)≥60 mm Hg; a carotid intima-media thickness (CIMT)>0.8 mm and a systolic pressure index (SPI)<0.9. Logistic regression was used in the statistical study of associations.
Results: A total of 321 PLWHIV on ART were recruited. The average age of PLWHIV was 51±11-years with a female pre dominance of 72% (n=231); the independent determinants of subclinical atherosclerosis were married (aOR: 4, 95% CI 1.5 10.5; p<0.006), low socio-economic status (aOR: 10.7, 95% CI 2.3-48, 7 p<0.002), duration of HIV infection (ORa: 6.6, 95% CI 2.8-16; p<0.0001), duration of antiretroviral treatment ≥9-years (ORa: 0, 3, 95% CI 0.2-0.7; p<0.005) and the total cholesterol/high-density lipoprotein-cholesterol ratio (CT/HDL-C) (ORa: 2, 95% CI 1.1-3.6; p=0.034). Dyslipidaemia (hyper low-density lipoprotein-cholesterol (LDL-C), hyper HDL-c and hypertriglyceridemia) has been identified in PLWHIV on DTG. The prevalence of subclinical atherosclerosis in PLWHIV on ART was 31.1% (n=116/321).
Conclusion: Married people, low socioeconomic level, duration of HIV infection, duration of antiretroviral treatment beyond 9-years, and the CT/HDL-C ratio are identified as independent determinants of subclinical atherosclerosis in PLWHIV on ART in Kinshasa hospitals. Dyslipidemia is found in PLWHIV on DTG and the prevalence of subclinical atherosclerosis among PLWHIV on ART is low compared to that of Côte d’Ivoire.
References
Hsue PY, Waters D. HIV infection and coronary heart disease: Mechanisms and management. Nat Rev Cardiol. 2019; 16(12): 745- 759. doi: 10.1038/s41569-019-0219-9
Serrano-Villar S, Gutiérrez F, Miralles C, et al. Human immuno-deficiency virus as a chronic disease: Evaluation and management of nonacquired immune deficiency syndrome-defining conditions. Open Forum Infect Dis. 2016; 3: ofw097. doi: 10.1093/ofid/ofw097
Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infec-tion as a chronic disease. Lancet. 2013; 382(9903): 1525-1533. doi: 10.1016/S0140-6736(13)61809-7
Legarth RA, Ahlstrom MG, Kronborg G, et al. Long-term mor-tality in HIV-infected individuals 50 years or older: A nationwide, population-based cohort study. J Acquir Immune Defic Syndr. 2016; 71(2): 213-218. doi: 10.1097/QAI.0000000000000825
Pillay-van WV, Msemburi W, Laubscher R, et al. Mortality trends and differentials in South Africa from 1997 to 2012: Second Na-tional Burden of Disease Study. Lancet Glob Health. 2016; 4(9): e642-e653. doi: 10.1016/S2214-109X(16)30113-9
Programme National de Lutte contre le VIH/SIDA (PNLS). Guide de prise en charge intégrée du VIH en République Démocratique du Congo. 2020. Website. https://hivpolicywatch. org/duremaps/data/guidelines-rename/DemocraticRepublicof-CongoARTguidelines2013.pdf. Accessed July 21, 2022.
Djalloh A-MA, Soya E, Ekou A, et al. Prévalence et détermi-nants de l’athérosclérose chez les patients infectés par le virus de l’immunodéficience humaine (VIH) et traités par les anti-rétro-viraux. [In: French]. JMV-J Médecine Vasc. 2018; 43(2): 115. doi: 10.1016/j.jdmv.2017.12.090
Kwiatkowska W, Knysz B, Arczynska K, et al. Peripheral arterial disease and ankle-brachial index abnormalites in young and mid-dle-aged HIV-positive patients in Lower Silesia, Poland. PLoS One. 2014; 9(12): e113857. doi: 10.1371/journal.pone.0113857 Original Research | Volume 9 | Number 1 | Murielle Longokolo M, et al
Olalla J, Salas D, De La Torre J, Del Arco A, Prada JL, Alegría JG. Ankle-brachial index in the assessment of cardiovascular risk among HIV infected patients. Rev Med Chil. 2011; 139(8): 1039- 1045.
Gee ME, Campbell N, Sarrafzadegan N, et al. Standards for the uniform reporting of hypertension in adults using population sur-vey data: Recommendations from the World Hypertension League Expert Committee. J Clin Hypertens (Greenwich). 2014; 16(11): 773- 781. doi: 10.1111/jch.12387
Desormais I, Amidou SA, Houehanou YC, et al. The preva-lence, awareness, management and control of hypertension in men and women in Benin, West Africa: The TAHES study. BMC Car-diovasc Disord. 2019; 19 (1): 303. doi: 10.1186/s12872-019-01273-7
Mukeba-Tshialala D, Nachega JB, Mutombo-Tshingwali M, Arendt V, Gilson G, Moutschen M. Obesity, high blood pressure, hypercholesterolaemia, and untreated diabetes in HIV-infected and HIV-uninfected Adults in Mbuji-Mayi (Democratic Republic of Congo). Bull Soc Pathol Exot. 2017; 110(5): 301-309. doi: 10.1007/ s13149-017-0561-2
Longo-Mbenza B, Apalata T, Longokolo M, et al. Associa-tion of Helicobacter pylori infection with the metabolic syndrome among HIV-infected black Africans receiving highly active antiret-roviral therapy. Cardiovasc J Afr. 2015; 26(2): 52-56. doi: 10.5830/ CVJA-2015-012
Kamdem F, Mapoure Y, Hamadou B, et al. Prevalence and risk factors of peripheral artery disease in black Africans with HIV infection: A cross-sectional hospital-based study. Vasc Health Risk Manag. 2018; 14: 401-408. doi: 10.2147/VHRM.S165960
Agu CE, Uchendu IK, Nsonwu AC, Okwuosa CN, Achukwu PU. Prevalence and associated risk factors of peripheral artery dis-ease in virologically suppressed HIV-infected individuals on anti-retroviral therapy in Kwara state, Nigeria: A cross sectional study. BMC Public Health. 2019; 19(1): 1143. doi: 10.1186/s12889-019- 7496-4
Taharboucht S, Guermaz R. L’index de pression systolique et la Non Alcoholic Fatty Liver Disease (NAFLD): Une étude cas -témoins. JMV-J Médecine Vasc. 2020; 45: S41. doi: 10.1016/j. jdmv.2020.01.099
Organisation Mondiale de la Santé (OMS). Lignes directri-ces consolidées sur l’utilisation des médicaments antirétroviraux pour le traitement et la prévention de l’infection à VIH: Recom-mandations pour une approche de santé publique. [In: French]. 2nd ed. 2016. Website. https://www.ncbi.nlm.nih.gov/books/ NBK374294/pdf/Bookshelf_NBK374294.pdf. Accessed July 21, 2022.
Cardio-online. Une athérosclérose infraclinique et une CRP élevée simultanées associées à un risque accru d'infarctus et d’AVC. [In: French]. 2018. Website. https://www.cardio-online.fr/Actu-alites/Depeches/Une-atherosclerose-infraclinique-et-une-CRP-elevee-simultanees-associees-a-un-risque-accru-d-infarctus-et-d-AVC. Accessed July 21, 2022.
Kidney International Supplements. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chron-ic Kidney Disease, Official Journal of the International Society of Nephrology, 2013. Website. https://kdigo.org/wp-content/ uploads/2017/02/KDIGO_2012_CKD_GL.pdf. Accessed July 21, 2022.
Tia WM, Nda JK, Kouame GR, Kobenan R, Daingui D, Ouat-tara B. Insuffisance rénale chronique: Aspects épidémiologique, di-agnostique, thérapeutique et évolutif au CHU de Bouaké de 2016 à 2020. [In: French]. Revue Africaine de Médecine Interne. 2022; 9 (2-2): 60-66.
de Gercourt TGJ. Prise en Charge de I’hyper Uricémie en Médecine Générale: Approche Qualitative. [In: French]. [master’s thesis]. Méde-cine Humaine et Pathologie: 2018. Website. https://dumas.ccsd. cnrs.fr/dumas-01901630v1/file/Girou%20Jayet%20de%20Ger-court%20Thibault.pdf. Accessed July 21, 2022.
Hong S, Han K, Park C-Y. The triglyceride glucose index is a simple and low-cost marker associated with atherosclerotic cardio-vascular disease: A population-based study. BMC Med. 2020; 18(1): 361. doi: 10.1186/s12916-020-01824-2
Thérapeutique. NOUVEAUTÉS 2016 EN DYSLIPIDÉMIE. [In: French]. 2016. Website. https://www.louvainmedical.be/fr/ article/nouveautes-2016-en-dyslipidemie. Accessed July 21, 2022.
Belalcazar S, Acosta EJ, Medina-Murillo JJ, Salcedo-Cifuentes M. Conventional biomarkers for cardiovascular risks and their correlation with the castelli risk index-indices and TG/HDL-C. Archivos de Medicina (Col). 2020; 20(1): 11-22. doi: 10.30554/ archmed.20.1.3534.2020
Olamoyegun MA, Oluyombo R, Asaolu SO. Évaluation de la dyslipidémie, des ratios lipidiques et de l’indice athérogène en tant que facteurs de risque cardiovasculaire chez les habitants semi-ur-bains au Nigeria. [In: French]. Ann Afr Med. 2016; 15(4): 194-199. doi: 10.4103/1596-3519.194280
Patil S, Rojulpote C, Gonuguntla K, et al. Association of tri-glyceride to high density lipoprotein ratio with global cardiac mi-crocalcification to evaluate subclinical coronary atherosclerosis in non-diabetic individuals. Am J Cardiovasc Dis. 2020; 10(3): 241-246.
Kocak MZ, Aktas G, Erkus E, Sincer I, Atak B, Duman T. Serum uric acid to HDL-cholesterol ratio is a strong predictor of metabolic syndrome in type 2 diabetes mellitus. Rev Assoc Med Bras (1992). 2019; 65(1): 9-15. doi: 10.1590/1806-9282.65.1.9
Psomas KC, Dixneuf M. VIH et vieillissement — Vivre avec le VIH à 50 ans et plus. [In: French]. vih.org. 2014. Website. https:// vih.org/20130205/vivre-avec-le-vih-a-50-ans-et-plus/. Accessed 12 Murielle Longokolo M, et al February 22, 2023.
Haddad N, Robert A, Popovic N, et al. Cas de VIH nouvel-lement diagnostiqués chez les personnes de 50 ans et plus, com-parativement aux personnes de moins de 50 ans: 2008 à 2017. [In: French]. Relevé Mal Transm Au Can. 2019; 45(11): 311-317. doi: 10.14745/ccdr.v45i11a02f
The Joint United Nations Programme on HIV/AIDS (UN-AIDS). Global AIDS Monitoring 2023: Indicators and questions for monitoring progress on the 2021 Political Declaration on HIV and AIDS. 2022. Website. https://www.unaids.org/sites/default/ files/media_asset/global-aids-monitoring_en.pdf. Accessed Feb-ruary 22, 2023.
Agbeko DK, Toyi T, Lihanimpo D, et al. Troubles lipidiques et glucidiques à risque cardio-vasculaires chez les personnes vi-vant avec le virus d’immunodéficience humaine sous traitement antirétroviral: cas du centre de prise en charge médicale de l’ONG Espoir-Vie-Togo à Lomé. [In: French]. Pan Afr Med J. 2019; 34: 203. doi: 10.11604/pamj.2019.34.203.20600
Tougouma J-B, Yaméogo AA, Yaméogo NV, et al. Fréquence élevée de l´ischémie myocardique asymptomatique dans une popu-lation de patients infectés par le VIH à Bobo-Dioulasso, Burkina Faso. [In: French]. Pan Afr Med J. 2021; 38: 173. doi: 10.11604/ pamj.2021.38.173.9509
O’Halloran JA, Satchell CS, Mallon PW. Dyslipidemia, athero-sclerosis and cardiovascular disease: An increasingly important triad in an aging population living with HIV. Future Virol. 2013; 8(10): 1021-1034. doi: 10.2217/fvl.13.87
Cresta M, Brun A, Merlet P, et al. Cardiopathie ischémique silencieuse chez les patients sous ARV: Prévalence et facteurs de risque. [In: French]. Médecine et Maladies Infectieuses Formation. 2022; 1(2 Suppl), S134-S135. doi: 10.1016/j.mmifmc.2022.03.293
European AIDS Clinical Society. EACS guidelines 9.0. 2017. Website. https://www.eacsociety.org/media/2017_guidelines_9.0- english_rev-20181024.pdf. Accessed February 22, 2023.
Ergin HE, Inga EE, Maung TZ, Javed M, Khan S. HIV, anti-retroviral therapy and metabolic alterations: A review. Cureus. 2020; 12(5): e8059. doi: 10.7759/cureus.8059
Marrakchi W, Kooli I, Harzallah G, Aouam A, Chakroun M. Évaluation du risque cardiovasculaire des personnes vivant avec le VIH en Tunisie: Un nouveau challenge pour améliorer la qualité de vie. [In: French]. Annales d’Endocrinologie. 2018; 79(4): 502. doi: 10.1016/j.ando.2018.06.1020
Blümer RM, van Vonderen MG, Sutinen J, et al. Zidovudine/ lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS Lond Engl. 2008; 22(2): 227-236. doi: 10.1097/QAD.0b013e3282f33557 Original Research | Volume 9 | Number 1 |
Mingou JS, Aw F, Sarr SA, et al. Dyslipidemia of patients living with HIV in DAKAR transversal study, case-wi tnesses, multicen-tric. PARIPEX - INDIAN JOURNAL OF RESEARCH. 2018; 7(1): 117-121.
Alvi RM. Protease inhibitors and cardiovascular outcomes in patients with HIV and heart failure. J Am Coll Cardiol. 2018; 72: 518-530. doi: 10.1016/j.jacc.2018.04.083
NAMSAL ANRS 12313 Study Group, Kouanfack C, Mpoudi-Etame M, Bassega PO, et al. Dolutegravir-based or low-dose efa-virenz-based regimen for the treatment of HIV-1. N Engl J Med. 2019; 381(9): 816-826. doi: 10.1056/NEJMoa1904340
Venter WF. Comparaison de 3 traitements de 1re ligne pour l’infection VIH en Afrique du Sud (essai ADVANCE). [In: French]. Paper presented at: 10th IAS Conference on HIV Science; 2019; Mexico City, Mexico, USA.
Abstract Supplement Oral Abstracts from the 23rd Interna-tional AIDS Conference, 6-10 July 2020. J Int AIDS Soc. 2020; 23(Suppl 4): e25547. doi: 10.1002/jia2.25547
Krikke M, Hoogeveen RC, Hoepelman AIM, Visseren FLJ, Ar-ends JE. Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease Submit your article to this journal | https://openventio.org/submit-manuscript/ Original Research | Volume 9 | Number 1 | Murielle Longokolo M, et al risk score (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE-NL) and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) risk prediction models. HIV Med. 2016; 17(4): 289-297. doi: 10.1111/hiv.12300
Tseng ZH, Moffatt E, Kim A, et al. Sudden cardiac death and myocardial fibrosis, determined by autopsy, in persons with HIV. N Engl J Med. 2021; 384(24): 2306-2316. doi: 10.1056/NEJ-Moa1914279
Deguenonvo GNC, Gaye AM, Thiam I, Dial CMM, Woto-Gaye G. Athérosclérose aortique et coronarienne au Sénégal: À propos d’une série autopsique de 116 patients d’origine africaine au CHNU Aristide Le Dantec (Dakar-Sénégal). [In French]. Ann Pathol. 2019; 39(1): 2-8. doi: 10.1016/j.annpat.2018.06.001
Fontaine J. Impact de la situation socio-économique sur l’observance des personnes vivant avec le VIH. [In: French]. 2021. Website. https://dumas.ccsd.cnrs.fr/dumas-03239445/document. Accessed February 22, 2023.
Izizag BB, Situakibanza H, Kiazayawoko F, et al. Déterminants de la non-observance au traitement antirétroviral chez l´adulte à Kinshasa. [In: French]. Pan Afr Med J. 2020; 37: 157. doi: 10.11604/ pamj.2020.37.157.13261
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in HIV/AIDS Research and Treatment (HRT) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
